Skip to main content
. 2018 Dec 5;2018:1300–1309.

Table 2.

Top 20-ranked repositioned drug candidates. NCT**: SCZ drugs from clinical trials. PMID**: SCZ drugs from biomedical literature. FDA-approved SCZ drugs are highlighted.

Rank Drug Evidence Rank Drug Evidence
1 quetiapine FDA-approved 11 clozapine FDA-approved
2 sertraline NCT00169988, NCT00531518 12 trazodone NCT00659919
3 risperidone FDA-approved 13 valproic acid NCT00194025,
NCT01094249,
NCT02011750
4 alprazolam PMID3289523,
PMID1348161,
PMID12516314
14 lithium NCT00202306
NCT00183443
NCT00202293
5 olanzapine FDA-approved 15 donepezil NCT01490567,
NCT00465283,
NCT00206947
6 fluoxetine NCT00531518,
NCT02022709
16 memantine NCT02001103
NCT00757978
NCT00097942
7 aripiprazole FDA-approved 17 sulpiride NCT00654576,
NCT02307396
8 citalopram NCT00893256,
NCT00047450,
NCT01032083,
NCT01032083
18 bupropion NCT01111149,
NCT00307203
9 haloperidol FDA-approved 19 lorazepam NCT00797277,
NCT00431184,
NCT00159133
10 levetiracetam PMID12609283,
PMID19265183
20 ziprasidone FDA-approved